TransMedics Group (NASDAQ:TMDX) Given New $110.00 Price Target at Needham & Company LLC

Key Points

• Needham raised its price target on TransMedics Group from $106 to $110 and maintained a Buy rating; the target implies 25.8% upside from the stock’s current price.
• TransMedics reported quarterly revenue of $203 million, up 41.1% year over year, and EPS of $0.51, beating analyst estimates. EPS was down from $0.66 a year earlier.
• The company raised its 2026 revenue guidance to $764 million–$774 million. Analyst views are mixed overall: MarketBeat reports a consensus Hold rating and an average target of $118.60.

TransMedics Group (NASDAQ:TMDX - Get Free Report) had its price objective boosted by investment analysts at Needham & Company LLC from $106.00 to $110.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has a "buy" rating on the stock. Needham & Company LLC's price objective would suggest a potential upside of 25.80% from the stock's current price.

Other equities research analysts have also recently issued research reports about the company. TD Cowen restated a "buy" rating and issued a $120.00 price target on shares of TransMedics Group in a research note on Tuesday, September 8th. Canaccord Genuity Group upped their price objective on shares of TransMedics Group from $95.00 to $120.00 and gave the company a "buy" rating in a report on Friday. UBS Group dropped their price objective on shares of TransMedics Group from $80.00 to $77.00 and set a "neutral" rating on the stock in a research report on Wednesday, August 5th. Piper Sandler reissued an "overweight" rating and issued a $100.00 price objective (down from $120.00) on shares of TransMedics Group in a research report on Wednesday, August 5th. Finally, Weiss Ratings upgraded shares of TransMedics Group from a "hold (c-)" rating to a "hold (c)" rating in a research note on Monday, August 31st. Five research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat.com, TransMedics Group currently has a consensus rating of "Hold" and a consensus target price of $118.60.

TransMedics Group Stock Performance

TransMedics Group stock traded up $18.46 during midday trading on Friday, reaching $87.44. 1,980,634 shares of the company's stock were exchanged, compared to its average volume of 1,010,329. The stock's 50-day simple moving average is $79.68 and its 200 day simple moving average is $93.44. The firm has a market cap of $3.02 billion, a price-to-earnings ratio of 22.29, a P/E/G ratio of 1.00 and a beta of 2.14. The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62. TransMedics Group has a 52 week low of $60.10 and a 52 week high of $156.00.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported $0.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.21. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%. The firm had revenue of $203.01 million for the quarter, compared to analyst estimates of $178.06 million. During the same quarter in the prior year, the company earned $0.66 earnings per share. The business's revenue for the quarter was up 41.1% compared to the same quarter last year. On average, analysts expect that TransMedics Group will post 1.46 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director David Weill purchased 1,336 shares of TransMedics Group stock in a transaction that occurred on Friday, September 11th. The stock was acquired at an average cost of $81.63 per share, for a total transaction of $109,057.68. Following the purchase, the director directly owned 16,392 shares of the company's stock, valued at $1,338,078.96. This trade represents a 8.87% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 6.90% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Braidwell LP raised its stake in TransMedics Group by 85.1% during the second quarter. Braidwell LP now owns 609,715 shares of the company's stock worth $40,497,000 after acquiring an additional 280,324 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of TransMedics Group by 5.5% in the first quarter. Dimensional Fund Advisors LP now owns 516,679 shares of the company's stock worth $51,355,000 after acquiring an additional 26,969 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of TransMedics Group by 6.1% in the 2nd quarter. Wellington Management Group LLP now owns 515,973 shares of the company's stock valued at $34,271,000 after purchasing an additional 29,500 shares in the last quarter. Congress Asset Management Co. boosted its stake in shares of TransMedics Group by 11.0% in the 3rd quarter. Congress Asset Management Co. now owns 252,952 shares of the company's stock valued at $21,109,000 after purchasing an additional 25,118 shares in the last quarter. Finally, Principal Financial Group Inc. grew its holdings in shares of TransMedics Group by 19.4% during the 1st quarter. Principal Financial Group Inc. now owns 231,433 shares of the company's stock valued at $23,007,000 after purchasing an additional 37,656 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

Trending Headlines about TransMedics Group

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Third-quarter revenue rose 41.1% year over year to $203 million, exceeding the roughly $178 million analyst estimate. Adjusted earnings were $0.51 per share, also above consensus. TransMedics third-quarter results
• Positive Sentiment: TransMedics raised its 2026 revenue guidance to $764 million–$774 million, signaling confidence in continued growth. Revenue guidance and catalysts
• Neutral Sentiment: Unusual options activity was reported after earnings, but the article does not indicate whether trading was bullish or bearish. Unusual options volume report
• Negative Sentiment: Despite beating estimates, quarterly EPS declined from $0.66 a year earlier to $0.51. The company also pushed the ENHANCE Part B and DENOVO catalysts to early 2027, potentially delaying related updates. Revenue guidance and catalysts

TransMedics Group Company Profile

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company's primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.

TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.